Alinix100 mg/5 ml

Alinix 100 mg/5 ml is a broad-spectrum antiprotozoal medication primarily prescribed for the treatment of infectious diarrhea caused by specific parasitic organisms. It is clinically indicated for infections involving:

• Cryptosporidium parvum – a protozoan parasite responsible for cryptosporidiosis, which causes watery diarrhea, especially in immunocompromised patients and young children.
• Giardia lamblia – the causative organism of giardiasis, a common intestinal infection linked to contaminated food or water.
• Entamoeba histolytica – responsible for amoebic dysentery and intestinal amoebiasis.

Because of its activity against these organisms, Alinix 100 mg/5 ml is widely used in regions where waterborne and foodborne parasitic infections are common, including Bangladesh, as part of standard diarrheal disease management protocols.

Always take Alinix 100 mg/5 ml strictly according to a registered physician's advice.

Alinix 100 mg/5 ml belongs to the therapeutic class of Anti-diarrhoeal Antiprotozoal agents, used specifically to target and eliminate parasitic organisms responsible for infectious diarrhea.

Alinix 100 mg/5 ml is a synthetic, orally administered antiprotozoal agent belonging to the thiazolide class of drugs. Its therapeutic action centers on disrupting the energy metabolism of susceptible parasites.

Mechanism of Action

Alinix 100 mg/5 ml interferes with the pyruvate ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction. This biochemical pathway is essential for anaerobic energy production in protozoa. By blocking this reaction, Alinix 100 mg/5 ml effectively halts the parasite's ability to generate energy, leading to its death.

Active Metabolite

After absorption, Alinix 100 mg/5 ml is rapidly converted to its active metabolite, tizoxanide. Both the parent compound and tizoxanide demonstrate in vitro activity against:

• Sporozoites and oocysts of Cryptosporidium parvum
• Trophozoites of Giardia lamblia

This dual-action mechanism contributes to Alinix 100 mg/5 ml's effectiveness as a first-line treatment option for parasitic gastrointestinal infections.

Alinix 100 mg/5 ml is highly bound to plasma proteins, which means it has the potential to interact with other medications that share this same binding characteristic.

Plasma Protein Binding Interactions

Caution should be exercised when Alinix 100 mg/5 ml is co-administered with other highly plasma protein-bound drugs that have a narrow therapeutic index. In such cases, competition for protein-binding sites may alter the free (active) concentration of either drug, potentially increasing the risk of toxicity or reducing therapeutic effectiveness.

Patients on anticoagulants, anti-epileptics, or other narrow therapeutic index medications should inform their physician before starting Alinix 100 mg/5 ml, so appropriate monitoring or dose adjustment can be considered.

Like all medications, Alinix 100 mg/5 ml may cause side effects, though most are mild and resolve on their own.

Common Side Effects

• Abdominal pain
• Vomiting
• Headache

These effects are typically mild and transient in nature, meaning they usually subside without needing to stop treatment.

Rare Side Effects

• Nausea
• Loss of appetite (anorexia)
• Flatulence
• Increased appetite
• Enlarged salivary glands
• Elevated creatinine and SGPT (liver enzyme) levels
• Pruritus (itching)
• Rhinitis
• Excessive sweating
• Dizziness
• Discolored urine

Patients experiencing severe or persistent side effects should consult their physician promptly.

Pregnancy

Alinix 100 mg/5 ml falls under US FDA Pregnancy Category B. This indicates that animal reproduction studies have not demonstrated a risk to the fetus; however, there are no adequate and well-controlled studies conducted in pregnant women. Since animal studies do not always predict human response accurately, Alinix 100 mg/5 ml should only be used during pregnancy if clearly needed and under medical supervision.

Lactation

Alinix 100 mg/5 ml has been shown to be excreted in human breast milk. Therefore, caution is advised when administering this medication to breastfeeding mothers. A healthcare provider should evaluate the benefits versus potential risks before prescribing Alinix 100 mg/5 ml during lactation.

Alinix 100 mg/5 ml should be administered with caution in the following patient groups:

• Hepatic and biliary disease: Patients with liver or bile duct disorders require close monitoring, as Alinix 100 mg/5 ml metabolism may be affected.
• Renal disease: Patients with kidney impairment should be monitored carefully during treatment, as drug clearance may be altered.

Physicians should assess a patient's full medical history before prescribing Alinix 100 mg/5 ml to minimize the risk of adverse effects.

• Store in a dry place, away from direct light and heat.
• Keep the medication out of the reach of children.
• Do not use beyond the expiration date printed on the packaging.
• For oral suspension, check bottle-specific storage instructions (e.g., discard remaining suspension after a specified number of days once reconstituted).